Moderna is now worth more than 3X as much as BioNTech. Which biotech stock is the smarter pick?
Is bigger always better? Not necessarily.
Model output · Signal date 2026-10-16
Biontech Se (BNTX) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Top 35%
of 5185 stocks scored
Rank correlation · 90D
4.0%
Spearman, 357 dates
Market Cap
$22.18B
large-cap · #7 of 60 peers
Summary
Biontech Se (BNTX) stock forecast summary
Our AI ranks Biontech Se outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Biontech Se is a large-cap company with a market capitalization of $22.18B. It ranks number 7 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its P/E Ratio of 2.27x is the lowest of the 15 peers that report one.
For BNTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 4.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -9.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BNTX included.
Follow BNTX freePrice
BNTX price chart and AI forecast
Cross-section · 2026-10-16
How BNTX ranks among 5185 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2025-12-31
Biontech Se (BNTX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric. Statement values were filed in EUR and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
Valuation & Market
| Metric | BNTX | Rank |
|---|---|---|
| Market Cap | $22.18B | 7/60 |
| P/E Ratio | 2.27x | 15/15 |
| EPS | $38.67 | – |
| Revenue/Share | $119.85 | – |
| FCF/Share | $83.21 | – |
Profitability & Margins
| Metric | BNTX | Rank |
|---|---|---|
| ROE | 44.5% | 4/47 |
| ROA | 38.9% | 2/50 |
| ROIC | 53.5% | 2/53 |
| Gross Margin | 82.1% | 8/24 |
| Operating Margin | 39.7% | 4/40 |
| Net Margin | 32.0% | 4/37 |
| EBT Margin | 46.4% | 2/42 |
| Tax Rate | 31.0% | – |
Financial Health
| Metric | BNTX | Rank |
|---|---|---|
| Current Ratio | 7.54x | 23/59 |
| Quick Ratio | 7.49x | 5/28 |
| D/E Ratio | 0.14x | 43/53 |
| Financial Leverage | 1.14x | 42/52 |
| Working Capital | $16.45B | 1/59 |
Cash Flow
| Metric | BNTX | Rank |
|---|---|---|
| Operating Cash Flow | $22.22B | 1/57 |
| Free Cash Flow | $21.04B | 1/50 |
| Capital Spending | -$1.18B | 49/50 |
| FCF Growth YoY | 0.0% | 10/15 |
| FCF/Sales | 69.4% | 1/32 |
| CapEx/Sales | 3.9% | 16/32 |
Operational Efficiency
| Metric | BNTX | Rank |
|---|---|---|
| Asset Turnover | 1.22x | 2/36 |
| Receivables Turnover | 28.9x | 2/24 |
| Inventory Turnover | 43.2x | 1/23 |
| Fixed Assets Turnover | 24.8x | 7/37 |
| Days Sales Outstanding | 13 days | 23/24 |
| Days Inventory | 8 days | 23/23 |
| Payables Period | 41 days | 17/26 |
| Cash Conversion Cycle | -20 days | 14/18 |
Income Statement
| Metric | BNTX | Rank |
|---|---|---|
| Total Revenue | $30.31B | 3/37 |
| Operating Income | $12.03B | 1/54 |
| Net Income | $9.70B | 1/50 |
| R&D Expense | $8.70B | 1/56 |
| Cost of Goods Sold | $5.41B | 3/26 |
Dividend & Shareholder Information
| Metric | BNTX | Rank |
|---|---|---|
| Shares Outstanding | 253M | – |
Balance Sheet Highlights (USD millions, converted from EUR)
| Total Current Assets | $18.97B | |
| Cash & Short-term Investments | $9.02B | |
| Accounts Receivable | $1.09B | |
| Inventory | $130M | |
| Total Liabilities | $3.25B | |
| Short-term Debt | $1.89B |
Quarterly Financial Reports
BNTX quarterly financials and insider trading
Industry Peers · Biological Products, (No Diagnostic Substances)
Biontech Se (BNTX) industry peers
Companies classified under the same SEC industry code as Biontech Se (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| BNTX Biontech Se | ▲ | $22.18B |
| AMGN Amgen Inc | ▼ | $233.82B |
| GILD Gilead Sciences, Inc. | ▶ | $193.67B |
| MRNA Moderna, Inc. | ▲ | $87.04B |
| ARGX Argenx Se | ▼ | $50.69B |
| RVMD Revolution Medicines, Inc. | ▲ | $38.14B |
| BIIB Biogen Inc. | ▼ | $34.13B |
| EXEL Exelixis, Inc. | ▼ | $15.42B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.83B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.79B |
| TECH Bio-Techne Corp | ▼ | $11.38B |
| QGEN Qiagen N.V. | ▶ | $10.01B |
| RGEN Repligen Corp | ▲ | $9.90B |
| IBRX Immunitybio, Inc. | ▲ | $9.73B |
| PCVX Vaxcyte, Inc. | ▲ | $9.47B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.37B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.71B |
| TWST Twist Bioscience Corp | ▲ | $8.32B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.17B |
| IMVT Immunovant, Inc. | ▲ | $5.52B |
| KOD Kodiak Sciences Inc. | ▲ | $5.39B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.86B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.76B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.83B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.57B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $2.99B |
| DNLI Denali Therapeutics Inc. | ▶ | $2.81B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.42B |
| ADMA Adma Biologics, Inc. | ▼ | $2.39B |
| LIFE Atyr Pharma Inc | ▲ | $2.37B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.07B |
| VCEL Vericel Corp | ▶ | $2.05B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $1.99B |
| NVAX Novavax Inc | ▲ | $1.86B |
| ALVO Alvotech | ▲ | $1.78B |
| MESO Mesoblast Ltd | ▶ | $1.70B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.69B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.53B |
| IMCR Immunocore Holdings Plc | ▼ | $1.51B |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.40B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.18B |
| VOR Vor Biopharma Inc. | ▲ | $1.07B |
| REPL Replimune Group, Inc. | ▲ | $1.02B |
| JATT Zura Bio Ltd | ▶ | $994M |
| IMTX Immatics N.V. | ▲ | $902M |
| MGTX Meiragtx Holdings Plc | ▶ | $891M |
| SLBT Sl Science Holding Ltd | ▶ | $873M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $832M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $831M |
| ODTX Odyssey Therapeutics, Inc. | ▶ | $825M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $692M |
| SANA Sana Biotechnology, Inc. | ▲ | $680M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $670M |
| AURA Aura Biosciences, Inc. | ▲ | $633M |
| PRME Prime Medicine, Inc. | ▲ | $629M |
| CADL Candel Therapeutics, Inc. | ▲ | $627M |
| SLDB Solid Biosciences Inc. | ▲ | $593M |
| DBVT Dbv Technologies S.A. | ▶ | $536M |
| VALN Valneva Se | ▼ | $521M |
Where BNTX sits on the market map
Life Sciences · Biological Products, (No Diagnostic Substances)
News
Biontech Se (BNTX) stock news
Why is BioNTech stock falling Tuesday?
On Tuesday, BioNTech SE BNTX reported initial findings from the AHEAD-MERIT Phase 2/3 clinical trial assessing BNT113, an ...
BioNTech SE: BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...
FAQ
Biontech Se (BNTX) stock forecast FAQ
What is the Biontech Se (BNTX) stock forecast?
Our AI ranks Biontech Se outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Biontech Se stock predictions?
For BNTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 4.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -9.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Biontech Se forecasts updated?
Biontech Se forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Biontech Se's industry peers?
60 issuers in our coverage, BNTX included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.